Key facts
- This page summarizes David McClung's Form 4 filing for BioCardia, Inc. (BCDA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 18 Apr 2022, 21:17.
David McClung - 14 Apr 2022 Form 4 Insider Report for BioCardia, Inc. (BCDA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- BCDA
- Reported as of
- 14 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Apr 2022, 21:17:31 UTC
- Prior SEC filing
- 11 Jun 2021
- Next SEC filing
- 07 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David McClung
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David McClung filed Form 4 for BioCardia, Inc. (BCDA) on 18 Apr 2022.
Change
- Previous filing in this sequence was filed on 11 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCDA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +50,345
- Change %
- +108%
- Price
- $0.000000
- Shares after
- 97,150
- Date
- 14 Apr 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCDA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +60,000
- Change %
- Price
- $0.000000
- Shares after
- 60,000
- Date
- 14 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 60,000
- Exercise price
- $1.49
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported securities are represented by restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. 100% of the RSUs vested on April 14, 2022.
Footnote F2
The option vests and becomes exercisable as to 1/48th of the shares on May 14, 2022, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.